Statistics for BILITE: A Bayesian randomized phase II design for immunotherapy by jointly modeling the longitudinal immune response and time-to-event efficacy
Total visits
| views | |
|---|---|
| BILITE: A Bayesian randomized phase II design for immunotherapy by jointly modeling the longitudinal immune response and time-to-event efficacy | 89 |
Total visits per month
| views | |
|---|---|
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
File Visits
| views | |
|---|---|
| Guo2020BILITE-AAM.pdf | 215 |
| java.util.UUID:4ebf68a5-7e32-44de-b6a0-77976a482f7d | 32 |
| java.util.UUID:ac86ee7d-d752-4988-8333-e5ea99e7cd49 | 3 |
| java.util.UUID:b6a5e13e-60d5-4ff8-a652-082f7dc1cfef | 1 |
Top country views
| views | |
|---|---|
| United States | 69 |
| Canada | 3 |
| Japan | 2 |
| Switzerland | 1 |
| China | 1 |
| Malaysia | 1 |
| Sweden | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 39 |
| Fairfield | 11 |
| Houston | 3 |
| Ann Arbor | 2 |
| Cambridge | 2 |
| Toronto | 2 |
| Washington | 2 |
| Baltimore | 1 |
| Beijing | 1 |
| Brugg | 1 |
| Lake Mary | 1 |
| Seremban | 1 |
| Spring | 1 |
| Umeå | 1 |
| Winnipeg | 1 |